<DOC>
	<DOCNO>NCT01017367</DOCNO>
	<brief_summary>The purpose study : 1. determine American College Rheumatology ( ACR ) 20 response rate Day 85 subject active rheumatoid arthritis ( RA ) administer MDX 1100 methotrexate ( MTX ) ; 2. determine tolerability safety multiple dose MDX-1100 combination MTX subject active RA .</brief_summary>
	<brief_title>Study MDX-1100 ( Anti-CXCL10 Human Monoclonal Antibody ) Combination With Methotrexate Subjects With Active Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>This Phase 2 , double-blind , placebo-controlled , randomize , multi-dose , multicenter study MDX 1100 ( anti CXCL10 human monoclonal antibody ) combination MTX subject active RA . All subject continue receive stable dos MTX ( 10 25 mg weekly ) study . Eligible subject ( n=70 ) randomize receive either placebo ( n=35 ) MDX-1100 ( n=35 ) 10 mg/kg intravenously , every week total 6 dos . Concomitant treatment stable dos prednisolone ( ≤ 10 mg/d , equivalent ) non-steroidal anti-inflammatory drug ( NSAIDS ) analgesic drug permit study , however , dose change Day 85 assessment complete unless rescue therapy require significant worsening symptom prior Day 85 . After Day 85 , subject follow Day 141 safety pharmacokinetics , change baseline medication addition new medication permit Investigator 's discretion . Non-steroid anti-inflammatory drug ( NSAIDS ) analgesic administer prior disease activity assessment study visit day . Subjects withdrawn prior Day 85 follow safety 70 day follow last dose study drug .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Must meet ACR criterion RA Must active RA , characterize least 6 66 swollen joint 6 68 tender joint , least 2 follow : serum Creactive protein level great upper limit normal , erythrocyte sedimentation rate &gt; = 28 mm per hour , morning stiffness &gt; 45 minute Seropositive rheumatoid factor , define plasma rheumatoid factor level least 20 IU per milliliter and/or seropositive anticyclic citrullinated peptide antibody Must MTX ( 10 25 mg weekly ) least 6 month receive stable dose 42 day randomization anticipate change MTX dose study Lowdose corticosteroid NSAIDs permit study entry must stable least 28 day randomization All disease modify nonbiologic antirheumatic drug ( DMARDs ) must discontinue least 28 day prior randomization except leflunomide ( discontinue least 60 day randomization ) . Etanercept ( discontinue least 28 day prior randomization ) infliximab , adalimumab , abatacept ( discontinue least 56 day prior randomization ) Screening laboratory value Hemoglobin ≥ 8.5 g/dL White blood cell ( WBC ) ≥ 3000/mm³ Neutrophils ≥ 1.5x10 ( 9 ) /L Platelets ≥ 125x10 ( 9 ) /L Serum creatinine &lt; 2 mg/dL Aspartate aminotransferase ( AST ) ≤ 2xULN Alanine aminotransferase ( ALT ) ≤ 2xULN Women must postmenopausal ( &gt; 12 month without menses ) surgically sterile use effective contraception least 4 week prior anticipate Visit 2 date agree continue contraception duration participation study Sexually active male subject must use barrier method contraception course study . Prior treatment B cell deplete therapy Any monoclonal antibody immunoglobulinbased fusion protein ≤ 8 week prior randomization Any experimental treatment ≤ 4 week prior randomization Primary secondary immunodeficiency Any autoimmune disease RA ( except concurrent Sjogren 's syndrome hypothyroidism ) Complications RA include : Active rheumatoid vasculitis Bed bound wheelchair bound Clinically significant pulmonary fibrosis Felty 's syndrome Any history malignancy , exclude adequately treat cured basal squamous cell carcinoma skin , cervical carcinoma situ Active major psychiatric disease Evidence acute chronic infection Clinically significant cardiac disease require medication , unstable angina , myocardial infarction within 6 month randomization , congestive heart failure Arrhythmia require active therapy , exception clinically insignificant extrasystole , minor conduction abnormality ; History cerebrovascular disease require medication/treatment ; Concomitant anticoagulation therapy know bleed disorder Seizure disorder require active therapy Known drug alcohol abuse Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>RA</keyword>
	<keyword>inflammatory joint disease</keyword>
</DOC>